TWiV reviews why children should be vaccinated against COVID-19, increased risk of infection with SARS-CoV-2 Beta, Gamma, and Delta variant compared to Alpha variant in vaccinated but not recovered individuals, and immune correlates of protection from the mRNA-1273 vaccine efficacy trial.
In COVID-19 clinical update #90, Dr. Griffin covers FDA expansion for booster doses, 3 more at home antigen tests approved by FDA, immune correlates analysis of mRNA-1273 vaccine, risk for stillbirth, PROVENT prophylaxis trial results, fluvoxamine recommendations, advice on molnupiravir, automated text messaging service for monitoring illness, and long COVID-19 after vaccination and infection.
In COVID-19 clinical update #89, Dr. Griffin reviews upcoming meeting on FDA emergency use authorization for molnupiravir, 25% of US cases in children, reinfection associates with presence of antibodies, national surveillance for acute flaccid myelitis in the US, and monoclonal antibody treatment of infection in vaccinated, high-risk individuals.
In COVID-19 clinical update #88, Dr. Griffin covers vaccine protection among US veterans, absence of long COVID in vaccinated who are infected, single dose of REGEN-COV monoclonal antibody cocktail provides long term protection, and Pfizer protease inhibitor Paxlovid is 89% effective in preventing hospitalization or death.
Greg Zuckerman joins TWiV to discuss his book that explores the race to produce COVID-19 vaccines, with insights into the companies, scientists, and executives involved and the rivalries, ambitions, ego, and a desire to save the world.
In COVID-19 clinical update #87, Dr. Griffin reviews PCR cycle threshold and RNA copy number, rapid antigen tests, hospitalization rate after infection or vaccination, allergies and vaccination, community transmission and viral RNA load, early treatment with sotrovimab, meta-analysis of tocilizumab treatment, antibiotic overuse, and guidelines on the use of anticoagulation for thromboprophylaxis.
In this special live-streamed episode of TWiV, Dr. Daniel Griffin fields questions on SARS-CoV-2 and COVID-19 from listeners.
In COVID-19 clinical update #86, Dr. Griffin discusses virologic features of infection in children, antibody tests should not be used to asses level of protection, test-to-stay programs in schools, FDA authorizes Moderna boosters, results of TOGETHER trial for fluvoxamine, statins and 28 day mortality, and cognitive function in patients.
Rich reviews the history of smallpox and the discovery of variola viral genomes in ancient DNA from human remains throughout Northern Europe, which pushes back the earliest date of smallpox virus infection to ~600–1050 CE, overlapping the Viking Age.
In COVID-19 clinical update #85, Dr. Griffin reviews cases and deaths by vaccination status, mRNA vaccine effectiveness in 12-18 year olds, standard and extended dosing of mRNA vaccines, immune responses after vaccination, Moderna booster dose approved, giving monoclonals at home, no benefit from colchicine, and IFN does not help remdesivir.
The Hosts of TWiV
Vincent Racaniello, Ph.D.
Brianne Barker, Ph.D.
Rich Condit, Ph.D.
Alan Dove, Ph.D.
Daniel Griffin, M.D.,
Ph.D., CTropMed CTH
Angela Mingarelli, DVM
Jolene Ramsey, Ph.D.
Kathy Spindler, Ph.D.